Key Developments For Hollis-Eden Pharmaceuticals Inc
Hollis-Eden Pharmaceuticals Inc (HEPH.O) (Consolidated Issue listed on NASDAQ Global Market)
Hollis-Eden Pharmaceuticals, Inc. Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies Of Apoptone
Hollis-Eden Pharmaceuticals, Inc. announced the preliminary results of its ongoing Phase I/II clinical trial with Apoptone (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). The interim results of the Phase I/II study, which is being conducted with participating member sites of the Prostate Cancer Clinical Trial Consortium (PCCTC), demonstrated that 47% of subjects who were radiographically evaluable for response had stable disease. With the assessment of progression every 56 days, the median time to progression was 107 days. 43% of the biochemically evaluable subjects experienced a drop in PSA during treatment, with 33% equal to or greater than a 50% decline. Individuals experienced increases in PSA with stable disease. Plasma PSA increases are expected because the mechanism of action is believed to involve inhibition of tumor cell proliferation while the androgen receptor transcription element is engaged, independent of the androgen receptor. This results in an increase in tumor cell PSA expression followed by induction of apoptosis, which releases PSA into circulation. As tumor cell death occurs, the PSA is expected to decline or stabilize.
Hollis-Eden Pharmaceuticals, Inc. Appoints Dr. James M. Frincke As President And CEO
Hollis-Eden Pharmaceuticals, Inc. announced that it has appointed James M. Frincke Ph.D. as President and Chief Executive Officer (CEO) of the Company.
Hollis-Eden Pharmaceuticals, Inc. Appoints Salvatore J. Zizza As Non-Executive Chairman-Form 8-K
Hollis-Eden Pharmaceuticals, Inc. announced in its Form 8-K that its Board of Directors (the Board) of the Company removed Richard Hollis, the Company's former Chief Executive Officer, as Chairman of the Board and appointed Salvatore J. Zizza, a current director, as the Non-Executive Chairman of the Board.
Hollis-Eden Pharmaceuticals, Inc. Announces Termination Of Richard Hollis As Chief Executive Officer-Form 8-K
Hollis-Eden Pharmaceuticals, Inc. announced in its Form 8-K that it has terminated the employment of Richard Hollis as the Company's Chief Executive Officer (the Termination). In connection with the Termination, effective March 18, 2009, the Special Committee of the Board appointed James M. Frincke as the Company's current Chief Operating Officer, to serve as the Company's interim Chief Executive Officer.
Hollis-Eden Pharmaceuticals, Inc. Announces Cost Cutting Measures
Hollis-Eden Pharmaceuticals, Inc. announced that, due to current economic and industry conditions, it is implementing an aggressive cost cutting plan in order to preserve capital and focus the Company's resources on advancing its TRIOLEX (HE3286) and APOPTONE (HE3235) clinical development programs. As a result of the actions taken, the Company is reducing its workforce by approximately 33%, or 20 employees, as well as freezing salaries and suspending bonuses for all Company employees, including the Company's executive officers.
